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Abstract
Background: The entry of human immunodeficiency virus (HIV-1) into host cells involves the interaction of the viral exterior
envelope glycoprotein, gp120, and receptors on the target cell. The HIV-1 receptors are CD4 and one of two chemokine
receptors, CCR5 or CXCR4.
Methodology/Principal Findings: We created proteoliposomes that contain CD4, the primary HIV-1 receptor, and one of
the coreceptors, CXCR4. Antibodies against CD4 and CXCR4 specifically bound the proteoliposomes. CXCL12, the natural
ligand for CXCR4, and the small-molecule CXCR4 antagonist, AMD3100, bound the proteoliposomes with affinities close to
those associated with the binding of these molecules to cells expressing CXCR4 and CD4. The HIV-1 gp120 exterior
envelope glycoprotein bound tightly to proteoliposomes expressing only CD4 and, in the presence of soluble CD4, bound
weakly to proteoliposomes expressing only CXCR4. The thermal stability of CD4 and CXCR4 inserted into liposomes was
examined. Thermal denaturation of CXCR4 followed second-order kinetics, with an activation energy (Ea) of 269 kJ/mol
(64.3 kcal/mol) and an inactivation temperature (Ti)o f5 6 uC. Thermal inactivation of CD4 exhibited a reaction order of 1.3, an
Ea of 278 kJ/mol (66.5 kcal/mol), and a Ti of 52.2uC. The second-order denaturation kinetics of CXCR4 is unusual among G
protein-coupled receptors, and may result from dimeric interactions between CXCR4 molecules.
Conclusions/Significance: Our studies with proteoliposomes containing the native HIV-1 receptors allowed an examination
of the binding of biologically important ligands and revealed the higher-order denaturation kinetics of these receptors.
CD4/CXCR4-proteoliposomes may be useful for the study of virus-target cell interactions and for the identification of
inhibitors.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) entry into
target cells is mediated by the viral envelope glycoproteins,
following interaction with the host cell receptors, CD4 and one of
two coreceptors, CCR5 or CXCR4 [1–3]. The HIV-1 envelope
glycoproteins are organized into trimers consisting of three gp120
exterior envelope glycoproteins and three gp41 transmembrane
envelope glycoproteins. The association of gp120 with gp41 in the
trimer is maintained by non-covalent bonds. The unliganded
HIV-1 envelope glycoproteins exist in a high-energy state. The
binding of gp120 to CD4 results in envelope glycoprotein
conformational changes that increase the affinity of gp120 for
CCR5 or CXCR4. CD4 binding also results in an alteration of the
gp120-gp41 relationship, leading to exposure of previously buried
gp41 ectodomain segments. Subsequent binding of gp120 to
CCR5 or CXCR4, which are members of the family of G protein-
coupled, 7-transmembrane segment receptors, is thought to trigger
additional conformational changes in the envelope glycoproteins.
These changes may release constraints on the metastable gp41
glycoprotein. The formation of a stable six-helix bundle by the
gp41 ectodomain is thought to drive the fusion of the viral and
target cell membranes.
For primary HIV-1 isolates, CD4 and either CCR5 or CXCR4
are required for entry into the host cell. Most transmitted and
early HIV-1 isolates use CCR5 as a coreceptor. In some HIV-1-
infected individuals, the viruses acquire the ability to use CXCR4
as a coreceptor. Besides the presence of CD4 and the chemokine
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13249receptors, the lipid composition of the target cell membrane has
also been suggested to influence the efficiency of virus-cell
membrane fusion.
CD4 [4] is a Type 1 membrane protein consisting of four
extracellular immunoglobulin-like domains (designated D1–D4), a
transmembrane segment, and a cytoplasmic tail. The two amino-
terminal CD4 domains (D1 and D2) contribute to the interaction with
the natural CD4 ligand, the major histocompatibility complex class II
(MHC II) protein, during the association of CD4-expressing T cells
with antigen-presenting cells [5]. CD4 mainly exists as a 55-kDa
monomer on cell surfaces, but can form weak dimers as a result of
interactions involving domains D3 and D4 [6]. The cytoplasmic tail of
CD4 is associated with a Src-family kinase, p56
lck [7,8], and
contributes to intracellular signaling in response to T-cell receptor
triggering [9]. CD4 is used as a receptor by human and simian
immunodeficiency viruses [10]. The viral gp120 glycoprotein binds
CD4 domain D1 exclusively. The other CD4 domains are not
absolutely required for HIV-1 entry, but contribute to the efficiency of
the entry process, perhaps by orienting and spatially positioning D1.
CXCR4 [11–13] isa Gprotein-coupledreceptor(GPCR)thatacts
as a receptor for the chemokine, CXCL12 (also known as stromal
cell-derived factor (SDF-1)) [14,15]. CXCR4 plays a role in fetal
development, trafficking of naı ¨ve lymphocytes, mobilization of
hematopoietic stem cells, migration of several types of neural cells,
and synaptic transmission [16,17]. CXCR4 has been implicated in
different types of cancer [18–20], in the WHIM (Warts, Hypogam-
maglobulinemia, Infection and Myelokathexis) syndrome [21,22], in
rheumatoid arthritis [23], and in the immune response during fungal
asthma [24]. CXCR4 is expressed on naı ¨ve T lymphocytes, which
are much more abundant than the CCR5-expressing, activated T
lymphocytes. Thus, the emergence of HIV-1 viruses that can utilize
CXCR4 as a coreceptor typically exposes a much larger population
of CD4-positive T lymphocytes to potential infection by HIV-1 and is
usually associated with a poorer prognosis.
Proteoliposomes that containthe HIV-1receptorscould be useful
tools in investigating the interaction of HIV-1 with target cells [25].
CD4-containing proteoliposomes have been produced [26–30] and
shown to bind specifically to HIV-1-infected cells [26,27].
Proteoliposomes containing CD4 and CCR5 also retain the ability
to bind cells expressing HIV-1 envelope glycoproteins [31].
Paramagnetic proteoliposomes, consisting of a paramagnetic bead
surroundedbyalipidmembranecontainingCCR5[32] orCXCR4
[33], have been used to study the binding of natural chemokine
ligands and HIV-1 gp120 glycoproteins. The gp120 glycoprotein of
CCR5-using HIV-1 isolates was shown to bind specifically to
CCR5-proteoliposomes in the absence of soluble CD4 (sCD4), but
bound more efficiently in the presence of sCD4 [32]. The specific
binding of gp120 glycoproteins from CXCR4-using HIV-1 variants
toCXCR4-proteoliposomeswas detected onlyafterincubationwith
sCD4, and occurred with a dissociation constant of 200 nM [33].
Thus, the HIV-1 receptors can retain the ability to bind the HIV-1
gp120 envelope glycoprotein after solubilization, purification and
reconstitution into proteoliposomes.
Here, we create proteoliposomes containing CD4 and CXCR4,
demonstrate the ability of these HIV-1 receptors to interact with
specific ligands, and investigate the thermal stability of these
membrane proteins.
Results
Preparation of proteoliposomes containing CD4 and
CXCR4
To create proteoliposomes, we used CHAPSO detergent to
solubilize human CD4 (expressed in 293T cells) and human
CXCR4 (expressed in Cf2Th cells). Both proteins have a C-
terminal C9 epitope tag, allowing capture and purification with
the 1D4 antibody complexed with Protein A-Sepharose CL-4B
beads. After washing, the CD4 and CXCR4 proteins were eluted
from the beads with the C12 peptide, which competes with the C9
epitope tag for the 1D4 antibody [34]. The eluted proteins were
then incorporated into liposomes by dialysis against glycerol-free
buffer in the presence of lipids. Proteoliposomes containing CD4,
CXCR4 and both CD4 and CXCR4 were prepared. The
proteoliposomes were freeze-thawed to enhance protein reconsti-
tution in the membrane [35–37] and to decrease lamellarity
[38–40], which can complicate interpretation of studies of
proteoliposomes [41].
In some experiments, the proteoliposomes were extruded
through polycarbonate filters. The non-extruded and extruded
CXCR4-proteoliposomes were studied by dynamic light scattering
and electron microscopy. The mean diameter of the non-extruded
proteoliposomes was found to be approximately 2,000 nm and
that of the extruded proteoliposomes around 200 nm (Figure S1).
The protein composition of the CD4-proteoliposomes and
CXCR4-proteoliposomes was analyzed by separation on reducing
and non-reducing SDS-polyacrylamide gels and silver staining. As
a negative control, we prepared CD4-free and CXCR4-free
liposomes from lysates of 293T cells and Cf2Th cells, respectively,
and analyzed these in parallel. The 1D4 antibody could be
detected in all of the liposomes (Figure S2). In addition, the
CXCR4 protein was detected in the CXCR4-proteoliposomes and
the CD4 protein in the CD4-proteoliposomes.
Antibody binding to CD4/CXCR4-proteoliposomes
To assess the conformation of the CD4 and CXCR4 molecules
incorporated into the proteoliposomes, we studied the binding of
phycoerythrin (PE)-labeled antibodies to CD4/CXCR4-proteoli-
posomes using flow cytometry. Two anti-CD4 antibodies, Q4120
[42] and RPA-T4 [43], were used. The Q4120 antibody
recognizes an epitope in the D1 domain of CD4 that is sensitive
to denaturation [44]. The RPA-T4 antibody binds to a D1 epitope
that involves the complementarity-determining region (CDR)
loops 1 and 3. Both antibodies bound to CD4/CXCR4-
proteoliposomes in a dose-dependent manner (Figure 1).
We also tested two antibodies, 12G5 [45] and 44717.111 [46],
that are directed against conformation-dependent epitopes on
CXCR4. The 12G5 antibody recognizes only a subset of CXCR4
conformations [46,47] and binds a complex epitope influenced by
the integrity of the CXCR4 second extracellular loop [47,48] and
the disulfide bond between cysteine residues 28 and 274 [47]. The
44717.111 antibody reacts preferentially with the second extra-
cellular loop of CXCR4 and is capable of binding multiple
CXCR4 conformations [46,47]. Both antibodies bound to CD4/
CXCR4-proteoliposomes in a dose-dependent manner (Figure 1).
The entire population of CD4/CXCR4-proteoliposomes stained
positively with an anti-CD4 and an anti-CXCR4 antibody,
indicating that essentially all of the proteoliposomes contain both
proteins. A control antibody, 2D7 [49], which is directed against
CCR5, did not bind the CD4/CXCR4-proteoliposomes efficiently
(data not shown). Moreover, none of the anti-CD4 or anti-
CXCR4 antibodies bound liposomes prepared without CD4 and
CXCR4. These results suggest that both CD4 and CXCR4 in the
proteoliposomes were in native conformations. The 12G5 and
44717.111 antibodies also bound to the extruded CXCR4-
proteoliposomes (data not shown), indicating that CXCR4 can
be individually reconstituted into extruded proteoliposomes in a
native state.
Heat Denaturation of CD4/CXCR4
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CXCR4-proteoliposomes were optimized by assessing the final
product with the Q4120 anti-CD4 antibody and the 12G5 anti-
CXCR4 antibody. These studies revealed that the use of glycerol-
free dialysis buffer resulted in a better yield of proteoliposomes
with conformationally correct CD4 and CXCR4 (data not shown).
The concentration of 1D4 antibody used to capture CD4 and
CXCR4 (1.1 mg/ml) and the concentration of C12 peptide used
to elute these proteins from the beads (200 mg/ml) were
determined by optimizing 12G5 antibody recognition. In a similar
manner, elution of CD4 and CXCR4 from the beads at room
temperature proved to be slightly better than elution at 4uC for
producing optimal levels of CD4 and CXCR4 recognized by the
conformation-dependent antibodies (data not shown). Recognition
by conformation-dependent anti-CD4 and anti-CXCR4 antibod-
ies was maintained for CD4/CXCR4-proteoliposomes stored at
4uC for at least 3–4 weeks, with an affinity comparable to that seen
for freshly prepared proteoliposomes (data not shown).
Binding of a small molecule to CD4/CXCR4-
proteoliposomes and cells
The bicyclam AMD3100 [50–53] is a small molecule
(molecular weight 830 Da) that specifically binds CXCR4 and
inhibits the infection of HIV-1 isolates that utilize CXCR4 as the
receptor [54]. The ability of AMD3100 to compete [46,55] with
the binding of PE-labeled 12G5 anti-CXCR4 antibody to CD4/
CXCR4-proteoliposomes and cells expressing CD4 and
CXCR4 was examined. At a 12G5 concentration of 1.25 mg/
ml, AMD3100 competed for binding of the antibody to
CXCR4-expressing Cf2Th cells with a half-maximal inhibitory
concentration (IC50) of 270 nM (Figure 2A). Of interest,
AMD3100 exhibited an IC50 of 70 nM when the 12G5
competition was performed with CD4/CXCR4-proteolipo-
somes. This suggests that AMD3100 binds better to CXCR4
on the surface of the proteoliposomes than on the cell surface.
The inhibition of 12G5 binding by AMD3100 was not as
complete for the CD4/CXCR4-proteoliposomes as for the
Figure 1. Binding of conformation-dependent monoclonal antibodies against CD4 and CXCR4 to CD4/CXCR4-proteoliposomes. The
indicated concentrations of PE-labeled monoclonal antibodies Q4120 (A), RPA-T4 (B), 12G5 (C) and 44717.111 (D) were incubated with CD4/CXCR4-
proteoliposomes. The mean fluorescence intensity at each antibody concentration was normalized to that seen at the highest antibody
concentration used. Each data point represents the mean and standard error derived from three independent experiments, each using a different
preparation of CD4/CXCR4-proteoliposomes.
doi:10.1371/journal.pone.0013249.g001
Heat Denaturation of CD4/CXCR4
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cooperativity or CXCR4 conformational states between the
proteoliposomes and cells. The observed inhibition was specific,
as AMD3100 did not inhibit the binding of the Q4120 and RPA-
T4 anti-CD4 antibodies either to CD4/CXCR4-proteolipo-
somes (Table S1) or to Cf2Th-CD4/CXCR4 cells (data not
shown). AMD3100 also inhibited 12G5 binding to extruded
CXCR4-proteoliposomes (data not shown). CCR5 antagonists,
TAK779 [56] and Compound A [57], did not inhibit 12G5
binding either to CD4/CXCR4-proteoliposomes (Table S1) or
to Cf2Th-CD4/CXCR4 cells (data not shown). We conclude
that AMD3100 binds efficiently to CXCR4 on the CD4/
CXCR4-proteoliposomes.
CXCL12 binding to CD4/CXCR4-proteoliposomes and
cells
We examined the binding of the natural CXCR4 ligand,
CXCL12 [14,15,58,59], to CD4/CXCR4-proteoliposomes.
The shorter, 68-residue a isoform [60] of CXCL12 was used
forthesestudies.CXCL12competed[46,55]with phycoerythrin
(PE)-labeled 12G5 antibody for binding to CXCR4. The ability
of increasing concentrations of CXCL12 to compete for 12G5
binding to CD4/CXCR4-proteoliposomes was compared
with the ability to compete for 12G5 binding to Cf2Th cells
expressing CD4 and CXCR4. The observed inhibitory curves
were almost identical (Figure 2B). When the concentration of the
12G5 antibody was 0.25 mg/ml, the half-maximal inhibitory
concentration (IC50) of CXCL12 was 110 nM for CD4/
CXCR4-proteoliposomes and 140 nM for CD4/CXCR4-ex-
pressing cells.
CXCL12 also inhibited the binding of the 44717.111 anti-CXCR4
antibody to the CD4/CXCR4-proteoliposomes, but did not compete
with the binding of the Q4120 and RPA-T4 anti-CD4 antibodies to the
proteoliposomes (data not shown). These data suggested that the
CXCR4 protein in the CD4/CXCR4-proteoliposomes binds
CXCL12 with an affinity similar to that of CXCR4 expressed on the
surface of cells.
Binding of HIV-1 gp120 to CD4-proteoliposomes and
CXCR4-proteoliposomes
FACS analysis was used to assess the binding of gp120 from the
CXCR4-using HIV-1HXBc2 strain to CXCR4-proteoliposomes, in
either the presence or the absence of sCD4. The bound gp120
molecules were detected with the human anti-gp120 antibody
2G12, followed by staining with a PE-labeled anti-human
antibody. Only in the presence of sCD4 was weak binding of
gp120 to the CXCR4-proteoliposomes detected above the
background levels of fluorescence observed in untreated cells or
cells incubated only with sCD4 (Figure 3A). These results are
consistent with the previously reported [33] low affinity of HIV-1
gp120 for CXCR4, even in the presence of sCD4.
By contrast, strong specific binding of gp120 to CD4-
proteoliposomes was detected (Figure 3B). The resulting mean
fluorescence intensity was approximately 16-fold greater than that
observed for gp120 binding to CXCR4-proteoliposomes in the
presence of sCD4. This is consistent with the significantly greater
affinity of gp120 for CD4 than for CXCR4.
Fusogenicity of proteoliposomes
Previous studies have suggested that the multilamellar nature of
liposomes can decrease their ability to participate in membrane
fusion events [61,62]. We evaluated the fusogenicity of extruded and
non-extruded proteoliposomes by a lipid mixing assay. Polyethylene
glycol (PEG)-mediated lipid mixing between proteoliposomes and
cells was studied using flow cytometry. Proteoliposomes were
synthesized in the presence of high concentrations of rhodamine-
labeled lipid; this results in self-quenching of the dye in the lipid
bilayer of the liposome. Should fusion occur with rhodamine-free
liposomes or cells, lipid mixing would lead to rhodamine dilution,
decreased quenching, and a net increase in rhodamine fluorescence
[63,64]. Both extruded and non-extruded CXCR4-proteoliposomes
participated in PEG-mediated fusion with 293T cells (Figure S3).
We next analyzed the ability of extruded proteoliposomes
containing the HIV-1 receptors to engage in a fusion reaction with
293T cells expressing the dual-tropic (CXCR4/CCR5-using)
Figure 2. Binding of AMD3100 and CXCL12 to CD4/CXCR4-proteoliposomes and CD4/CXCR4-expressing cells. The indicated
concentrations of AMD3100 (A) or CXCL12 (B) were added to CD4/CXCR4-proteoliposomes (filled circles) or Cf2Th-CD4/CXCR4 cells (open circles) in
the presence of 1.25 mg/ml (A) or 0.25 mg/ml (B) PE-labeled anti-CXCR4 antibody 12G5. The mean fluorescence intensity at each concentration of
AMD3100 or CXCL12 was normalized to the maximum value observed in the series. Each data point represents the mean and standard error derived
from three independent experiments. Each of the three experiments with CD4/CXCR4-proteoliposomes used a different preparation of CD4/CXCR4-
proteoliposomes.
doi:10.1371/journal.pone.0013249.g002
Heat Denaturation of CD4/CXCR4
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with a plasmid containing the deleted DKS env gene. The
expression of the HIV-1 envelope glycoproteins on the surface of
293T cells transfected with the plasmid containing the intact HIV-
1 env gene, but not the deleted DKS env gene, was confirmed by
staining with the 2G12 anti-gp120 antibody (data not shown).
These 293T cells were incubated with either CD4-proteolipo-
somes or CD4/CXCR4-proteoliposomes. The DKS-transfected
or HIV-1KB9 envelope-expressing 293T cells demonstrated a
similar level of fluorescence following incubation with rhodamine-
labeled CD4-proteoliposomes. Incubation of CD4/CXCR4-
proteoliposomes with DKS-transfected cells resulted in a higher
background level of fluorescence than was observed for the CD4-
proteoliposomes; the basis for this background is unknown. The
fluorescence increase associated with the incubation of CD4/
CXCR4-proteoliposomes with 293T cells expressing the HIV-
1KB9 envelope glycoproteins was slightly greater than that
observed with the control DKS-transfected 293T cells (Figure
S4). These results are consistent with a low level of HIV-1
envelope glycoprotein-dependent fusion occurring between the
envelope-expressing 293T cells and the CD4/CXCR4-proteolipo-
somes.
Thermal denaturation of CXCR4
Because proteoliposomes can withstand a wider range of
temperatures than living cells, the availability of proteoliposomes
containing the HIV-1 receptors provided an opportunity to
examine the effects of temperature on the native conformation
of these membrane proteins. The binding of a conformation-
dependent ligand has been used to assess the degree of
denaturation of some GPCRs following heat treatment [65–68].
Recognition of CXCR4 by four different conformation-dependent
antibodies, as well as by CXCL12 and HIV-1 gp120, has been
shown to be equivalently sensitive to detergent denaturation of
CXCR4 [33,69,70]. To study the heat inactivation of CXCR4, we
chose the conformation-dependent 12G5 anti-CXCR4 antibody
[45]. We examined the interaction, at room temperature, of the
PE-labeled 12G5 antibody with CD4/CXCR4-proteoliposomes
that had been incubated at different temperatures for various
times. The fluorescence observed for CD4/CXCR4-proteolipo-
somes incubated in parallel and then stained with a PE-labeled
anti-CCR5 antibody, 2D7, was subtracted from the values
observed with the 12G5 antibody.
Incubation at higher temperatures resulted in progressively
greater denaturation of CXCR4 (Figure 4A). When the natural
logarithm of the remaining fluorescent staining by the 12G5
antibody (F) was plotted versus time, the non-linearity of the curves
indicated that the thermal denaturation of CXCR4 did not follow
first-order kinetics (Figure 4B). To determine the order of the
thermal denaturation reaction, F
12n at 55uC and 60uC (where
sufficient denaturation occurred to make the measurements
reliable) was fitted to equation (5) (See Materials and Methods).
The correlation coefficient (r
2) and the ordinate intercept (b) were
close to 1 when the reaction order, n, was 2 (Figures 4C and 4D).
Thus, the thermal denaturation of CXCR4 is a second-order
reaction and equation (5) can be written as:
F{1{1~Kappt
where t is time and Kapp is the apparent reaction rate.
The F
2121 versus time plots (Figure 4E) revealed the expected
straight lines; the apparent reaction rates (Kapp) at each
temperature were derived from the slopes of these lines (Table 1).
The half-lives (t1/2) and decimal reduction time (D) (time
required for 90% reduction in 12G5 antibody binding) were
obtained for the second-order thermal denaturation of CXCR4 at
each temperature from equations (7) and (9) (See Materials and
Methods):
t1=2~1=Kapp
D~9=Kapp
The calculated t1/2 and D values for CXCR4 at each
temperature are shown in Table 1.
The Z value, a measure of the temperature dependence of the
denaturation reaction rate, can be determined from a plot of
log10D versus temperature (Figure 5A). The calculated Z value for
CXCR4 is 7.5uC.
Figure 3. Binding of HIV-1 gp120 to CXCR4-proteoliposomes and CD4-proteoliposomes. The binding of HIV-1HXBc2 gp120 to CXCR4-
proteoliposomes (A) or CD4-proteoliposomes (B) is shown. In some of the experiments shown in (A), soluble CD4 (sCD4) was added at a concentration
of 80 mg/ml. The bound gp120 was detected by incubation of the proteoliposomes with the 2G12 anti-gp120 monoclonal antibody, followed by a PE-
labeled goat anti-human antibody. The values shown represent the averages of the mean fluorescence intensities from 2–4 experiments.
doi:10.1371/journal.pone.0013249.g003
Heat Denaturation of CD4/CXCR4
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13249Figure 4. Temperature stability of CXCR4 in CD4/CXCR4-proteoliposomes. (A) The fluorescent staining of CD4/CXCR4-proteoliposomes
with the PE-labeled anti-CXCR4 antibody 12G5 after incubation for the indicated time at the given temperature is shown. The F value represents the
fluorescent staining relative to that observed in the absence of heat treatment of the CD4/CXCR4-proteoliposomes. Each data point represents the
mean and standard error derived from three independent experiments, in which three different proteoliposome preparations were used. (B) The
Heat Denaturation of CD4/CXCR4
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temperature at which the t1/2 of thermal denaturation is
10 minutes, can be found from a plot of log10t1/2 versus
temperature (Figure 5A). The inactivation temperature for
CXCR4 is 56.0uC.
The activation energy (Ea) of the denaturation reaction (the
minimal energy required to initiate the reaction) can be
determined from a plot of ln Kapp versus reciprocal temperature
(Figure 5B). The activation energy for the thermal denaturation of
CXCR4 is 269 kJ/mol, or 64.3 kcal/mol.
Thermal denaturation of CD4
The thermal inactivation of CD4 in the CD4/CXCR4-
proteoliposomes was studied by examining the binding, at room
temperature, of the PE-labeled anti-CD4 antibody Q4120 to the
proteoliposomes that had been preincubated at different temper-
atures for various times. The fluorescence observed with the anti-
CCR5 antibody 2D7 was subtracted from the values observed
with the Q4120 antibody.
CD4 staining by the Q4120 antibody decreased faster than
CXCR4 staining by the 12G5 antibody (compare Figures 4A and
6A). Because the plots of ln F versus time were not linear
(Figure 6B), the thermal denaturation of CD4, like that of
CXCR4, apparently does not follow first-order kinetics. Fitting of
F
12n to equation (5) at 55uC and 60uC suggested that the order (n)
of the CD4 thermal denaturation is close to 1.3 (Figure 6C). The
determination of the reaction order using the ordinate intercept b
yields similar values (n=1.2 for 55uC and n=1.1 for 60uC)
(Figure 6D). For n=1.3, equation (5) can be written:
F{0:3{1~0:3Kappt
and the apparent reaction rate (Kapp) at each temperature can be
calculated, using the slopes of the plots in Figure 6E.
Using equations (7) and (9) respectively, the t1/2 and D values at
each temperature can be calculated:
t1=2~(20:3{1)=(0:3Kapp)
D~(100:3{1)=(0:3Kapp)
The values of Kapp,t 1/2 and D are presented in Table 1.
From a plot of log10D versus temperature (Figure 5A), the value
of Z was calculated to be 7.3uC. From the plot of log10t1/2 versus
temperature (Figure 5A), the value for Ti was calculated to be
52.2uC.
The activation energy Ea of 278 kJ/mol=66.5 kcal/mol of the
CD4 denaturation reaction was derived from a plot of ln Kapp
versus reciprocal temperature (Figure 5B).
Discussion
Proteoliposomes containing HIV-1 coreceptors, individually or
together with CD4, have been reported [31–33]. Here we
produced proteoliposomes containing CD4 and CXCR4. The
CD4 and CXCR4 proteins in the proteoliposomes are in native
conformations, based on recognition by HIV-1 gp120 and
monoclonal antibodies. Moreover, CXCR4 in the proteolipo-
somes binds CXCL12, the natural ligand, and AMD3100, a small-
molecule inhibitor of HIV-1 infection. Binding of CXCL12 to
CXCR4, for example, involves interaction of the chemokine with
the N terminus and extracellular loops 2 and 3 of CXCR4 [58,60],
supporting the assertion that CXCR4 in the proteoliposomes is in
a native conformation. Unlike paramagnetic proteoliposomes used
previously, the CD4/CXCR4-proteoliposomes studied here
presumably have CD4 and CXCR4 molecules randomly oriented
in either direction in the membrane; however, unlike the case for
paramagnetic proteoliposomes, CD4 and CXCR4 in our
proteoliposomes are not constrained with respect to lateral
movement in the membrane. The lateral mobility may be helpful
in allowing more natural clustering of receptor molecules bound to
the HIV-1 envelope glycoprotein complex [70–73].
The specific interaction of the extruded CD4/CXCR4-
proteoliposomes with cells expressing the HIV-1 envelope
glycoproteins was studied. However, the background fluorescence
signal associated with the interaction of the CD4/CXCR4-
proteoliposomes with control cells not expressing envelope
glycoproteins was significantly higher than that of CD4-proteoli-
posomes. The basis for this high background advises caution in
interpreting the higher fluorescence associated with the interaction
of CD4/CXCR4-proteoliposomes and cells expressing the HIV-1
envelope glycoproteins. Although some of the observed increase in
fluorescence may result from bona fide membrane fusion, further
work will be required to increase the efficiency of this process. For
example, it has been suggested that glycosphingolipids in the target
membrane play an important role in membrane fusion mediated
natural logarithm of F is shown as a function of time of incubation at the indicated temperatures. Note the non-linearity of the curves. (C) The
correlation coefficient, r
2, of the function F
12n is shown for the fitting of the experimental data on CXCR4 thermal denaturation at 55uC and 60uCt o
equation (5) for the indicated reaction order n. (D) The intercept with the ordinate axis b of the function F
12n is shown for the fitting of the
experimental data on CXCR4 thermal denaturation at 55uC and 60uC to equation (5) for the indicated reaction order n. (E) The value F
2121a sa
function of the time of incubation of CD4/CXCR4-proteoliposomes at the indicated temperature is shown.
doi:10.1371/journal.pone.0013249.g004
Table 1. Parameters of the thermal denaturation of CXCR4 and CD4 incorporated in CD4/CXCR4-proteoliposomes.
CXCR4 CD4
T(uC) Kapp (1/min) Half-life (min) D value (min) Kapp (1/min) Half-life (min) D value (min)
45 0.0038 263 2368 0.0086 89.6 386
50 0.0151 66.4 598 0.0342 22.5 97
55 0.0658 15.2 137 0.1923 4.01 17.3
60 0.3813 2.62 23.6 0.9385 0.82 3.54
doi:10.1371/journal.pone.0013249.t001
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will address whether CD4/CXCR4-proteoliposomes prepared
with modified lipid compositions, including glycosphingolipids,
will act as more efficient targets for HIV-1 envelope glycoprotein-
mediated membrane fusion.
The thermal stability of the HIV-1 receptors has not been
studied in detail. The integrity of the conformation-dependent
CCR5 epitope recognized by the 2D7 antibody was preserved
after exposure of CCR5-paramagnetic proteoliposomes to 50uC
[32], but the denaturation of CCR5 in this context was not
studied. We found that the thermal denaturation of CXCR4 is a
second-order reaction. This was unexpected, as the heat
inactivation of several other G protein-coupled receptors (rhodop-
sin [80–82], phoborhodopsin [83], 5-HT4 receptor [84] and M1
muscarinic acetylcholine receptor [66]) proceeds through first-
order reactions.
Various models have been proposed to explain second-order
thermal denaturation reactions of proteins [84]. Two models, the
model of parallel reactions [85] and the series-type model [86–88],
are usually applied. According to the model of parallel reactions,
two (or more) protein isoforms (E1,E 2, …), each with a different
level of heat resistance, exist. These isoforms are converted to
inactive forms (In) in parallel first-order reactions at rates governed
by the constants kn:
E1 ?
k1 I1,E2 ?
k2 I2,:::
In the simplest case involving only two isoforms, the fraction (F) of
the protein in the native conformation at time t is given as follows:
F~F1 exp({k1t)zF2 exp({k2t)
where F1 and F2 are the fractions of the native protein in each
isoform at time t=0. Note that, if F is normalized (F ; 1 at t=0),
then F1+F2=1.
According to a series-type model, protein inactivation proceeds
in the following manner:
E1?E2?:::?Em?I
where E2,… ,E m are intermediate protein conformations, I is the
inactivated conformation, and the first-order reactions E1RE2,
…, EmRI proceed at rates described by the rate constants k1,… ,
km. In the simplest case involving two steps (E1RE2RI) where
the protein proceeds to complete inactivation in the final
conformation,
F~½1zbk1=(k2{k1) |exp({k1t){½bk1(k2{k1) |exp({k2t)
where b is the time-independe n tc o n s t a n t[ 8 8 ] .
The equations for both the two-isoform parallel reaction model
and the two-step series-type model can be written [67]:
F~a1 exp({k1t)za2 exp({k2t)
where a1 and a2 are constants. To estimate k1 and k2, we fitted the
experimental data on the normalized 12G5 reactivity with CD4/
CXCR4-proteoliposomes at various times after 60uC incubation
to this equation. (The 1-min incubation time point at 60uC was
excluded because it is too short compared with the time required
for the sample to reach 60uC). This yielded the following results:
k1=0.046 min
21 and k2=0.376 min
21 (r
2=0.9993), which
correspond to respective half-lives of 15.0 and 0.26 minutes for
each of the two reactions.
Even in cell lysates, most or all of the CXCR4 molecules are
dimeric [89]. Dimerization of CXCR4 provides a natural
explanation of the observed second-order kinetics of denaturation.
Dimeric CXCR4, by virtue of a greater number of molecular
contacts with the partner subunit, is expected to exhibit better
stability, as has been observed for other protein dimers ([90–95]
Figure 5. Activation energies and Z values for the thermal denaturation of CD4 and CXCR4 in CD4/CXCR4-proteoliposomes. (A) The
decimal logarithm of the D value and half-life (t1/2) of native CD4 and CXCR4 in the CD4/CXCR4-proteoliposomes is shown as function of the absolute
temperature. The Z values were derived from the slopes of the plots for log10D, and the Ti values from the slopes and ordinate intercepts of the plots
for log10t1/2.( B) An Arrhenius plot shows the relationship of ln Kapp and the reciprocal of the absolute temperature for CD4 and CXCR4 denaturation
in the CD4/CXCR4-proteoliposomes. The slopes of these plots were used to determine the Ea values.
doi:10.1371/journal.pone.0013249.g005
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the PE-labeled anti-CD4 antibody Q4120 after incubation for the indicated time at the given temperature is shown. The F value represents the
fluorescent staining relative to that observed in the absence of heat treatment of the CD4/CXCR4-proteoliposomes. Each data point represents the
mean and standard error derived from three independent experiments, in which three different proteoliposome preparations were used. (B) The
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or all of the CXCR4 starts out as the more heat-stable dimer, but
upon incubation at 60uC, converts into more labile monomers,
explains the available data. Indeed, dissociation [96,97] or
formation [98–100] of protein oligomers has been proposed as a
possible mechanism underlying second-order kinetics of protein
denaturation and renaturation, respectively. Although weaker
than CXCR4 dimerization, the previously described CXCR4-
CD4 interactions [101] could also contribute to the observed
kinetics of CXCR4 denaturation.
We also evaluated the thermal denaturation of CD4 in the
CD4/CXCR4-proteoliposomes. The heat-induced denaturation
of other immunoglobulin superfamily members has been previ-
ously studied. CD4 in the CD4/CXCR4-proteoliposomes (acti-
vation energy of the denaturation reaction, Ea=278 kJ/mol) was
less thermostable than human and bovine immunoglobulin G
(Ea=315–393 kJ/mol) [102–106], bovine milk IgA (Ea=567 kJ/
mol), bovine milk IgM (Ea=421 kJ/mol) [103], or the MHC class
II molecule I-E
K (Ea=427 kJ/mol) [107]. The multi-chain nature
of immunoglobulin molecules may confer additional stability
through inter-chain contacts [106] that would not be available to
the single-chain CD4 molecule. It is also possible that the epitope
for the Q4120 antibody in domain D1 of CD4, the integrity of
which was used to monitor the native state of CD4 in the CD4/
CXCR4-proteoliposomes, is more sensitive to heat than the
immunoglobulin fold per se.
The order of the thermal denaturation of CD4 was found to be
close to 1.3. Various reaction orders between 1 and 2 inclusive
have been reported in the literature for the thermal denaturation
of immunoglobulins [102–104,106,108,109]. This is not surpris-
ing, given the multi-chain and oligomeric nature of the
immunoglobulins. Indeed, it has been pointed out that the
denaturation of proteins belonging to the immunoglobulin
superfamily can be complex, involving several reactions with
different temperature dependencies [110,111]. Likewise, the weak
dimerization of CD4 [6] and/or irreversible aggregation may
contribute to the fractional (n=1.3) order of the thermal
denaturation of CD4.
Studies of the thermal sensitivity of membrane proteins like
CD4 and CXCR4 in the context of different proteoliposome
configurations should increase our understanding of how interac-
tions with lipids and other proteins contribute to the structure and
function of these biologically important molecules. Furthermore,
proteoliposomes provide a useful system to assess mutagenic
approaches designed to stabilize membrane proteins for structural
studies [112–117].
Materials and Methods
Materials
1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), choles-
terol, 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE),
sphingomyelin (from porcine brain), and 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl)
(RhDOPE) were purchased from Avanti Polar Lipids, Inc.
(Alabaster, AL). Ammonium sulfate (NH4)2SO4, sodium chloride
(NaCl) and glycerol were purchased from Fisher Scientific
(Pittsburgh, PA). UltraPure Tris, zeocin, Dulbecco’s modified Eagle
medium (DMEM), and fetal bovine serum (FBS) were purchased
from Invitrogen (Carlsbad, CA). Protein A-Sepharose CL-4B beads
were purchased from GE Healthcare (Uppsala, Sweden). Hygro-
mycin B in PBS, polyethylene glycol (PEG) 1500 (50% wt/vol
solution in 75 mM HEPES) and complete mini EDTA-free
protease inhibitor cocktail tablets were purchased from Roche
(Mannheim, Germany). Glycine was purchased from ICN Bio-
medicals (Irvine, CA). Dulbecco’s phosphate-buffered saline (D-
PBS) without Ca
+2 or Mg
+2, penicillin-streptomycin solution,
trypsin-EDTA solution and G418 sulfate were purchased from
Mediatech, Inc. (Herndon, VA). Sodium butyrate, EDTA, EGTA,
and R-phycoerythrin (PE)-labeled anti-human CD4, clone Q4120
were purchased from Sigma-Aldrich (St. Louis, MO). CHAPSO [3-
[(3-Cholamidopropyl) dimethylammonio]-2-hydroxy-1-propane-
sulfonate] was purchased from Anatrace, Inc. (Maumee, OH).
PE-labeled anti-human CCR5, clone 2D7; PE-labeled anti-human
CXCR4, clone 12G5; and PE-labeled anti-human CD4, clone
RPA-T4 were purchased from BD Biosciences Pharmingen (San
Jose, CA). PE-labeled anti-human CXCR4, clone 44717.111 was
purchased from R&D Systems (Minneapolis, MN). CXCL12a (also
known as SDF-1a) was purchased from PeproTech, Inc. (Rocky
Hill, NJ). C12 peptide (VSKTETSQVAPA) was purchased from
American Peptide Company (Sunnyvale, CA). HEPES was
purchased from Boston BioProducts, Inc. (Worcester, MA). Human
anti-gp120 monoclonal antibody 2G12 and small-molecule
CXCR4 antagonist AMD3100 were obtained from the NIH AIDS
Research and Reference Reagent Program (Germantown, MD).
SolubleCD4was produced in293T cellsafterstable transfection or,
in some cases, was purchased from ImmunoDiagnostics, Inc.
(Woburn, MA). The 1D4 murine monoclonal antibody directed
against the C9 peptide (TETSQVAPA) was obtained from the
National Cell Culture Center (Minneapolis, MN). TAK779 was
generously provided by Takeda Pharmaceuticals (Deerfield, IL).
Compound A was generously provided by Merck (Whitehouse
Station, NJ).
Aqueous buffers
Solubilization buffer S1 had the following composition:
100 mM (NH4)2SO4, 20 mM Tris (pH 7.5), 10 vol % glycerol,
1% (weight:volume) CHAPSO, and protease inhibitor cocktail
(1 mini tablet per 10 ml). Solubilization buffer S2 had the
following composition: 100 mM (NH4)2SO4, 20 mM Tris
(pH 7.5), 1% (weight:volume) CHAPSO, and protease inhibitor
cocktail (1 mini tablet per 10 ml). Glycerol-free dialysis buffer had
the following composition: 100 mM (NH4)2SO4 and 20 mM Tris
(pH 7.5). Glycerol-containing dialysis buffer had the following
composition: 100 mM (NH4)2SO4, 20 mM Tris (pH 7.5) and
10 vol % glycerol.
Preparation of lipid mixture
Lipids (in chloroform solutions) were pooled in cryovials (a total
of 13.5 mmole in each cryovial) and dried under vacuum until all
of the solvent was removed. The lipid mixture from each cryovial
was then resuspended in 1 ml D-PBS and sonicated using the
Branson Sonifier 450 (Misonix, Inc., Farmingdale, NY). Sonicated
lipid mixture was stored under argon at 230uC. Except as
natural logarithm of F is shown as a function of time of incubation at the indicated temperatures. Note the non-linearity of the curves. (C) The
correlation coefficient, r
2, of the function F
12n is shown for the fitting of the experimental data on CD4 thermal denaturation at 55uC and 60uCt o
equation (5) for the indicated reaction order n. (D) The intercept with the ordinate axis b of the function F
12n is shown for the fitting of the
experimental data on CD4 thermal denaturation at 55uC and 60uC to equation (5) for the indicated reaction order n. (E) The value (F
20.321)/0.3 as a
function of the time of incubation of CD4/CXCR4-proteoliposomes at the indicated temperature is shown.
doi:10.1371/journal.pone.0013249.g006
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following composition: 35% DOPC, 30% DOPE, 15% sphingo-
myelin, and 20% cholesterol (so-called ‘‘nature’s own’’ fusogenic
lipid composition) [118]. The composition of the lipid mixture is
given as the molar ratio between component lipids.
Preparations of CXCR4-proteoliposomes used in the dynamic
light scattering experiments, in electron microscopy, and in the
studies of antibody and AMD3100 binding to extruded proteo-
liposomes were made with the following lipid composition: 40 mol
% DOPC, 40 mol % sphingomyelin, and 20 mol % cholesterol.
293T cells expressing CD4 containing the C9 tag
293T cells stably expressing human CD4 containing the C9
peptide (TETSQVAPA) at the C terminus were made by
Christoph Grundner, using the pcDNA3.1+ plasmid (Invitrogen,
Carlsbad, CA).
Cf2Th cells expressing CXCR4 containing the C9 tag
Cf2Th cells stably expressing human CXCR4 containing the
C9 peptide (TETSQVAPA) at the C terminus are described
elsewhere [33].
Cell culture
Cells were grown at 37uC with 5% CO2. CXCR4-free Cf2Th
cells and CD4-free 293T cells were grown in DMEM supple-
mented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin
and 100 mg/ml streptomycin (complete DMEM). Cf2Th cells
stably expressing human CXCR4 and CD4 were grown in
complete DMEM containing 0.2 mg/ml zeocin and 0.2 mg/ml
hygromycin B. Cf2Th cells stably expressing human CXCR4
containing C9 peptide at the C terminus and 293T cells stably
expressing human CD4 containing C9 peptide at the C terminus
were grown in complete DMEM containing 0.5 mg/ml G418.
Preparation of cell lysates
Cell lysates were prepared the following way. Cells grown to full
confluency in a 150-mm dish were treated for 24 hours with
complete DMEM containing 3 mM sodium butyrate prior to
harvest, detached by treatment with D-PBS/5 mM EDTA,
pelleted, washed in D-PBS, again pelleted, and stored at 230uC
until needed. Frozen cells were solubilized with S1 solubilization
buffer (,5610
7 cells in 1 ml of buffer) at 4uC for 45 minutes on a
rocking platform. Cell debris were pelleted by centrifugation for
30 minutes at 16,0006ga t4 uC, and the cleared lysate was stored at
230uC. For the preparation of the CXCR4-containing cell lysate,
Cf2Th cells stably expressing human CXCR4 containing the C9
peptide at the C terminus were used. For the preparation of the
CD4-containing cell lysate, 293T cells stably expressing human
CD4 containing the C9 peptide at the C-terminus were used. For
the preparation of CXCR4-free cell lysate, Cf2Th cells were used.
For the preparation of CD4-free cell lysate, 293T cells were used.
Formation of proteoliposomes
Approximately 1.5 g of Protein A-Sepharose CL-4B beads were
washed 4 times with 45 ml of water and then resuspended in
,7 ml of D-PBS/0.01% sodium azide and stored at 4uC.
One volume of the solution of Protein A-Sepharose CL-4B
beads was washed twice with solubilization buffer S1 and then
resuspended in 0.4 volumes of the solution of the 1D4 antibody at
a concentration of 1.1 mg/ml (a mixture of 0.08 volumes of the
stock solution (5.5 mg/ml) of 1D4 and 0.32 volumes of
solubilization buffer S1). Then beads were incubated overnight
at 4uC on a rocking platform. The beads were then washed three
times with solubilization buffer S1, and resuspended in 0.5
volumes of the same buffer. This bead suspension was aliquoted,
400 ml in each aliquot. To each aliquot, 1 ml of cell lysate was
added. (For the preparation of CXCR4-proteoliposomes or CD4-
proteoliposomes, CXCR4-containing lysate or CD4-containing
lysate, respectively, was used. For the preparation of CD4/
CXCR4-proteoliposomes, a mixture of 33.3 vol % of CXCR4-
containing lysate and 66.7 vol % of CD4-containing lysate was
used). The beads were incubated with the cell lysate for at least
2 hours at 4uC on a rocking platform.
Next, the beads were washed 5 times with solubilization buffer
S2 and then CXCR4 (and/or CD4) was eluted in the following
manner. Beads in each aliquot were incubated for 1 hour at room
temperature with 200 ml of a 200 mg/ml solution of peptide C12 (a
mixture of 160 ml of the solubilization buffer S2 and 40 ml of the
stock aqueous solution (1 mg/ml) of C12 peptide) on a rocking
platform. The beads were pelleted, supernatants containing the
eluted material were collected, and a second round of elution was
carried out. The two eluted solutions were combined. After
centrifugation to remove the beads, supernatants were collected.
A suspension consisting of the eluted material and the lipid
mixture in D-PBS was prepared (90 vol % of eluted material and
10 vol % lipid mixture in D-PBS). This suspension was dialyzed
overnight at 4uC against glycerol-free dialysis buffer (unless stated
otherwise), using a 10-kDa molecular weight cutoff (Slide-A-Lyzer
10 K; Pierce, Rockford, IL) to remove detergent and the C12
peptide and allow the formation of proteoliposomes. After five
freeze-thaw cycles, proteoliposomes were stored at 4uC.
The CXCR4-proteoliposomes used in the dynamic light
scattering experiments, in electron microscopy, and in the studies
of antibody and AMD3100 binding to extruded proteoliposomes
were prepared using solubilization buffer S1 instead of S2 and
dialysis against glycerol-containing buffer.
Protein-free liposomes were prepared using dialysis of the
mixture of 90 vol % solubilization buffer S1 and 10 vol % lipid
mixture in D-PBS against glycerol-containing dialysis buffer.
Formation of extruded proteoliposomes
Proteoliposomes (prepared as described above) were extruded
several times through two polycarbonate Nucleopore filters of 100-
nm pore size in a pressure extruder (Northern Lipids, Burnaby,
BC, Canada) to produce large unilamellar vesicles. All prepara-
tions were extruded at 37uC; the temperature during extrusion was
maintained with a circulating water bath (Voigt Global Distribu-
tion, Lawrence, KS). Liposomes prepared by extrusion through
100-nm pore size filters were homogeneous and fusogenic ([119],
and references therein).
Characterization of proteoliposome size
The size of non-extruded and extruded CXCR4-proteolipo-
somes was determined by dynamic light scattering (using a Coulter
N4 Plus submicron particle analyzer) and electron microscopy.
Electron microscopy was carried out as follows. Five ml of each
sample was absorbed to a formvar/carbon-coated grid for
1 minute and excess liquid was blotted off using Whatman #1
filter paper. The grid was stained with 1% uranyl acetate for
1 minute, blotted with a filter paper again and examined in a
Tecnai Spirit BioTwin transmission electron microscope at the
Electron Microscopy Core facility (Harvard Medical School,
Boston, MA).
Analysis of protein composition of the proteoliposomes
The protein composition of proteoliposomes was analyzed by
silver staining on an SDS-polyacrylamide gel as follows.
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utes in 16SDS loading buffer containing 5% b-mercaptoethanol
(b-ME) from Bio-Rad Laboratories, Inc. (Hercules, CA) (reducing
conditions) or in loading buffer without b-ME (non-reducing
conditions). Samples were run on SDS-polyacrylamide gels and
analyzed by silver staining using GelCode SilverSNAP (Pierce,
Rockford, IL) kit, as described by the manufacturer.
Antibody binding to CD4/CXCR4-proteoliposomes
The binding of anti-CXCR4 and anti-CD4 antibodies to CD4/
CXCR4-proteoliposomes was analyzed by fluorescence-activated
cell sorting (FACS). Proteoliposomes were incubated for 45 min-
utes at room temperature in D-PBS/3% fetal bovine serum (FBS)
containing varying concentrations of R-phycoerythrin (PE)-labeled
monoclonal antibody, in a volume of 100 ml. After this incubation,
200 ml of D-PBS/3% FBS was added to each sample. All samples
were analyzed with a FACScan flow cytometry using CellQuest
software (Becton Dickinson, San Jose, CA) in the FL2 channel.
Fluorescence of proteoliposomes incubated with varying concen-
trations of PE-labeled anti-CCR5 monoclonal antibody 2D7 was
subtracted, as a baseline, from all fluorescence measurements
obtained with specific antibodies.
CXCL12 binding to CD4/CXCR4-proteoliposomes and
Cf2Th-CD4/CXCR4 cells
The binding of the CXCR4 ligand CXCL12 to CD4/CXCR4-
proteoliposomes was analyzed by FACS using a competition assay
[46,55]. Proteoliposomes were incubated in D-PBS/3% FBS
containing various concentrations of CXCL12 in a final volume of
100 ml. Incubation for 20 minutes at room temperature in the
absence of antibody, was followed by incubation for 45 minutes at
room temperature, in the presence of 0.25 mg/ml of PE-labeled
anti-CXCR4 monoclonal antibody 12G5. After this incubation,
200 ml of D-PBS/3% FBS was added to each sample. All samples
were analyzed with a FACScan flow cytometry as described
above. Fluorescence of proteoliposomes incubated with 0.125 mg/
ml of PE-labeled anti-CCR5 monoclonal antibody 2D7, in the
absence of CXCL12, was subtracted, as a baseline, from all
fluorescence measurements obtained with the 12G5 antibody.
The ability of CXCL12 to compete for the binding of the 12G5
antibody to Cf2Th-CD4/CXCR4 cells was studied as described
above for proteoliposomes.
In control experiments, the binding of 0.12 mg/ml of PE-labeled
anti-CD4 monoclonal antibody Q4120, 0.125 mg/ml of PE-
labeled anti-CD4 monoclonal antibody RPA-T4, and 0.25 mg/
ml of PE-labeled anti-CXCR4 monoclonal antibody 44717.111 to
CD4/CXCR4-proteoliposomes was studied in the absence of
CXCL12 and in the presence of 500 nM of CXCL12.
AMD3100 binding to CD4/CXCR4-proteoliposomes and
Cf2Th-CD4/CXCR4 cells
The binding of the small-molecule CXCR4 antagonist
AMD3100 to CD4/CXCR4-proteoliposomes was analyzed by
FACS using a competition assay [47,55]. Proteoliposomes were
incubated in D-PBS/3% FBS containing various concentrations of
AMD3100 in a final volume of 100 ml. Incubation for 20 minutes
at room temperature, in the absence of antibody, was followed by
incubation for 45 minutes at room temperature in the presence of
1.25 mg/ml of PE-labeled anti-CXCR4 monoclonal antibody
12G5. After this incubation, 200 ml of D-PBS/3% FBS was added
to each sample. All samples were analyzed with a FACScan flow
cytometry as described above. Fluorescence of proteoliposomes
incubated with 0.625 mg/ml of PE-labeled anti-CCR5 monoclonal
antibody 2D7, in the absence of AMD3100, was subtracted, as a
baseline, from all fluorescence measurements obtained with the
12G5 antibody.
The ability of AMD3100 to compete for the binding of the
12G5 antibody to Cf2Th-CD4/CXCR4 cells was studied as
described above for proteoliposomes.
In control experiments, the binding of 0.6 mg/ml of PE-labeled
anti-CD4 monoclonal antibody Q4120 and 0.625 mg/ml of PE-
labeled anti-CD4 monoclonal antibody RPA-T4 to CD4/
CXCR4-proteoliposomes and Cf2Th-CD4/CXCR4 cells was
studied in the absence of AMD3100 and in the presence of
0.241 mM of AMD3100.
In other control experiments, the binding of 1.25 mg/ml of PE-
labeled anti-CXCR4 monoclonal antibody 12G5 to CD4/
CXCR4-proteoliposomes and Cf2Th-CD4/CXCR4 cells was
studied in the absence of any ligand and in the presence of
2.4 mM TAK779 or Compound A, small-molecule CCR5
antagonists.
Antibody and AMD3100 binding to extruded CXCR4-
proteoliposomes
The binding of anti-CXCR4 monoclonal antibodies 12G5 and
44717.111 and the small-molecule CXCR4 antagonist AMD3100
to extruded CXCR4-proteoliposomes (and, as a control, to non-
extruded CXCR4-proteoliposomes and to extruded and non-
extruded protein-free liposomes) was analyzed in the following
manner.
Liposomes were incubated with 25 mlo f4 - mm-diameter
aldehyde/sulfate latex beads (Interfacial Dynamics, Portland,
OR) in a final volume of 150 ml for 55 minutes at room
temperature, followed by a 90-minute incubation in 1 ml D-PBS
with gentle shaking. The reaction was stopped by incubation for
30 minutes in D-PBS supplemented with 100 mM glycine.
Liposome-coated beads were washed three times with D-PBS/
3% FBS and resuspended in 50 ml of D-PBS/3% FBS.
For the study of the antibody binding to liposomes, the
liposome-coated beads were incubated for 45 minutes at room
temperature in D-PBS/3% FBS containing 0.625 mg/ml of PE-
labeled anti-CXCR4 monoclonal antibody 12G5 or 1.25 mg/ml of
PE-labeled anti-CXCR4 monoclonal antibody 44717.111, in a
volume of 100 ml. For the study of AMD3100 binding to liposomes
using the competition assay, the liposome-coated beads were
incubated in D-PBS/3% FBS containing 0.241 mM AMD3100 in
a final volume of 100 ml. Incubation for 20 minutes at room
temperature, in the absence of antibody, was followed by
incubation for 45 minutes at room temperature in the presence
of 0.625 mg/ml of PE-labeled anti-CXCR4 monoclonal antibody
12G5.
After incubation, 500 ml of D-PBS/3% FBS was added to each
sample. All samples were analyzed with a FACScan flow
cytometry as described above. Fluorescence of liposome-coated
beads incubated with 0.625 mg/ml of PE-labeled anti-CCR5
monoclonal antibody 2D7, in the absence of AMD3100, was
subtracted, as a baseline, from all fluorescence measurements
obtained with CXCR4-specific antibodies.
Production of gp120 glycoprotein
Soluble HIV-1HXBc2 gp120 glycoprotein was prepared in the
following manner. Approximately 3.5610
6 293T cells were seeded
in a T75 tissue culture flask one day before transfection. Cells were
co-transfected with 9 mg of pSVIIIenv and 1 mg of pLTR-Tat
plasmids using the Polyfect transfection reagent (Qiagen, German-
town, MD). The supernatant was harvested 48 hours later, cleared
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The amount of gp120 was quantified by Western blot analysis.
Binding of soluble gp120 to CXCR4-proteoliposomes and
CD4-proteoliposomes
The binding of soluble HIV-1HXBc2 gp120 to CXCR4-
proteoliposomes and CD4-proteoliposomes was analyzed by
FACS. Proteoliposomes were incubated for 2 hours at 37uCi na
total volume of 100 ml, containing HIV-1HXBc2 gp120. As a
control, proteoliposomes were incubated for 2 hours at 37uC
without gp120. Incubation of CXCR4-proteoliposomes was
carried out in the presence of 80 mg/ml of soluble CD4 (or, as a
control, in the absence of soluble CD4). Proteoliposomes were
then centrifuged for 10 minutes at 20,8006g and resuspended in
100 ml of D-PBS/3% FBS containing 5 mg/ml of the human
monoclonal antibody 2G12, which recognizes a carbohydrate
epitope on the gp120 outer domain [120,121]. Proteoliposomes
were incubated for 45 minutes at room temperature, centrifuged
for 10 minutes at 20,8006g and resuspended in 100 ml of D-PBS/
3% FBS containing 5 ml of goat anti-human PE-labeled IgG
antibody (Jackson ImmunoResearch Laboratories, West Grove,
PA). Proteoliposomes were then incubated for 45 minutes at room
temperature. After this incubation, 200 ml of D-PBS/3% FBS was
added to each sample. All samples were analyzed with a FACScan
flow cytometry as described above.
PEG-mediated lipid mixing between cells and CXCR4-
proteoliposomes
CXCR4-proteoliposomes (lipid composition: 35 mol % DOPC,
25 mol % DOPE, 15 mol % sphingomyelin, 20 mol % choles-
terol, 5 mol % RhDOPE), prepared using solubilization buffer S1
instead of S2 and glycerol-containing dialysis buffer, were used.
Polyethylene glycol (PEG)-mediated lipid mixing between 293T
cells and CXCR4-proteoliposomes was studied in the following
manner. Cells were detached by treatment with D-PBS/5 mM
EDTA, pelleted, washed in D-PBS, again pelleted, and resus-
pended in D-PBS/3% FBS. Samples (total volume 360 ml each)
containing D-PBS, 100 ml of cell suspension, 10 ml of the
suspension of CXCR4-proteoliposomes and 120 ml of the PEG
solution in HEPES buffer (or, as a control, not containing PEG)
were incubated for 1 hour at 37uC. After this incubation, samples
were analyzed with a FACScan flow cytometry as described
above.
Plasmids and transfection
The plasmids that express the HIV-1KB9 envelope glycoprotein
[122] and the HIV-1 Tat protein, and a plasmid containing the
deleted DKS env gene were prepared using the Plasmid Maxi Kit
(Qiagen, Germantown, MD).
To prepare cells expressing the HIV-1KB9 envelope glycopro-
teins, 293T cells were co-transfected in T75 tissue culture flasks
with the HIV-1KB9 Env-expressing plasmid and an HIV-1 Tat-
expressing plasmid using the calcium phosphate precipitation
method (Invitrogen, Carlsbad, CA). Control cells were prepared in
the same manner, except that the plasmid containing the deleted
DKS env gene was used instead of the Env-expressing plasmid.
Surface expression of the HIV-1 envelope glycoproteins on Env-
transfected 293T cells was analyzed by FACS in the following
manner. Cells were detached by treatment with D-PBS/5 mM
EDTA, pelleted, washed in D-PBS, pelleted again, and resus-
pended in 50 ml of D-PBS/3% FBS containing 5 mg/ml of human
monoclonal antibody 2G12, which recognizes a carbohydrate
epitope on the gp120 outer domain [120,121]. Cells were
incubated for 1 hour at room temperature, pelleted and washed
in D-PBS/3% FBS twice, and then pelleted and resuspended in
100 ml of D-PBS/3% FBS containing 2 ml of goat anti-human PE-
labeled IgG antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA). Cells were then incubated for 1 hour at room
temperature. After this incubation, cells were pelleted, washed in
D-PBS/3% FBS, pelleted, resuspended in 500 ml of D-PBS/3%
FBS and then analyzed with a FACScan flow cytometry as
described above.
Cell-proteoliposome interactions
For the study of cell-proteoliposome interactions, transfected
293T cells and fluorescently labeled extruded proteoliposomes
were used. Interaction of cells transfected with plasmids that
express the functional HIV-1KB9 envelope glycoproteins or that
contains the deleted DKS env gene with either CD4/CXCR4-
proteoliposomes or CD4-proteoliposomes was studied.
Extruded CD4/CXCR4-proteoliposomes and CD4-proteolipo-
somes were prepared using a lipid mixture of the following
composition: 35 mol % DOPC, 25 mol % DOPE, 15 mol %
sphingomyelin, 20 mol % cholesterol, and 5 mol % RhDOPE.
Hence, these proteoliposomes contain a fluorescent rhodamine-
labeled lipid probe in a self-quenching concentration.
Transfected 293T cells were harvested 48 hours after transfec-
tion: cells were detached by treatment with D-PBS/5 mM EDTA,
pelleted, washed in D-PBS, pelleted again, and resuspended in
complete DMEM. The concentration of cells was adjusted to
3610
5 cells/ml, and 3610
5 cells were seeded in each well of a 24-
well plate. Cells were incubated at 37uC with 5% CO2 overnight.
The following day, 80 ml of proteoliposome suspension (or, as a
control, D-PBS) was added to each well of cells. Proteoliposomes
were incubated with cells for 8.5 hours at 37uC with 5% CO2. The
medium was then removed, and cells were harvested in 1 ml D-
PBS, pelleted and washed in D-PBS twice, and then pelleted and
resuspended in 500 ml of D-PBS. All samples were then analyzed
with a FACScan flow cytometry as described above. Each of the
experimental conditions was studied in parallel triplicate experi-
ments and the results averaged.
Thermal denaturation of CXCR4 and CD4 molecules
incorporated in CD4/CXCR4-proteoliposomes
After the incubation of CD4/CXCR4-proteoliposomes at
different temperatures for various periods of time, the binding of
anti-CXCR4 and anti-CD4 antibodies to these proteoliposomes
was analyzed by FACS. Suspensions of proteoliposomes were
incubatedatdifferenttemperaturesfordifferentperiodsoftime,and
immediately placed on ice. Afterwards, proteoliposomes were
incubated for 45 minutes at room temperature in D-PBS/3%
FBS containing 1.25 mg/ml of the PE-labeled anti-CXCR4
monoclonal antibody 12G5, 0.6 mg/ml of the PE-labeled anti-
CD4 monoclonal antibody Q4120, or 0.625 mg/ml of the PE-
labeled anti-CCR5 monoclonal antibody 2D7 in a volume of
100 ml. After this incubation, 200 ml of D-PBS/3% FBS was added
to each sample. All samples were analyzed with a FACScan flow
cytometry as described above. The fluorescence of proteoliposomes
incubated with the2D7antibody was subtracted, asa baseline,from
all fluorescence measurements obtained with the 12G5 and Q4120
antibodies. Each experiment was performed in triplicate and
employed proteoliposomes from three separate preparations.
Kinetic analysis of the protein denaturation reaction
The rate of the protein denaturation reaction at particular
temperature can be generally described by the formula:
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where C is the concentration of undenatured protein at time t, n is
the reaction order, and k is the reaction rate constant at this
temperature [123]. If n=1 (i. e., if denaturation follows first-order
kinetics), integration of (1) yields:
C=C0~exp({kt) ð2Þ
where C0 is the value of C at time t=0 (i. e., the initial protein
concentration).
If n?1, integration of (1) yields:
(C=C0)
1{n~1z(n{1)Kappt, ð3Þ
where Kapp=kC 0
n21; here, Kapp is the apparent denaturation rate
constant, with k being the true rate constant.
In our experiments, the initial concentration of protein C0 is
unknown and, hence, if the denaturation reaction does not follow
first-order kinetics, we cannot find the true denaturation rate
constant k. However, we assume that C/C0 is equal to F, which is
defined as the specific fluorescence of proteoliposomes associated
with the binding of a conformation-dependent antibody, normal-
ized to the specific fluorescence observed for proteoliposomes that
were not heated. Therefore, equation (2) can be rewritten as:
1nF~{kt ð4Þ
Thus, if thermal inactivation is a first-order reaction, the value
of k can be obtained from the plot of ln F versus t.
Likewise, equation (3) can be rewritten as
F1{n~1z(n{1)Kappt ð5Þ
The function F
12n versus t should be a straight line (i. e., the
correlation coefficient r
2 should be close to 1), and the ordinate
intercept b (at t=0) of this line should be close to 1, if the process
follows the estimated reaction order. Then, if (F
12n21)/(n21) is
plotted versus t, the value of Kapp equals the slope of the plotted
line.
Half-lives and decimal reduction times of the thermal
denaturation can be calculated for each temperature. The half-
lives (t1/2) of the thermal denaturation (time required for 50%
denaturation at constant temperature) can be calculated using the
formula:
t1=2~(1n2)=k ð6Þ
for first-order kinetics, and
t1=2~(2n{1{1)=½(n{1)Kapp ð 7Þ
for non-first-order kinetics.
Similarly, D values (decimal reduction time, i. e., time required
for 90% denaturation at constant temperature [102,103]) can be
calculated using the formula
D~(1n10)=k ð8Þ
for first-order kinetics, and
D~(10n{1{1)=½(n{1)Kapp ð 9Þ
for non-first-order kinetics.
Activation energies and Z values associated with thermal
denaturation of proteins
Two models, the Arrhenius model and the Bigelow model, have
been used to describe the thermal denaturation of proteins. The
Arrhenius model is based on the assumption that the logarithm of
the denaturation reaction rate constant k decreases linearly with
an increase in reciprocal temperature. By contrast, in the Bigelow
model, the logarithm of k increases linearly with an increase in
temperature. By using the Arrhenius model, the activation energy
Ea of the denaturation reaction can be calculated. By using the
Bigelow model (also known as thermal death time (TDT) model),
one can calculate the Z value, a measure of the temperature
dependence of the denaturation reaction rate.
Strictly speaking, the assumptions underlying these two models
contradict each other [124]. However, the general belief is that
both methods can be used satisfactorily, within a relatively short
temperature range [125]. Often, as in this study, both models are
employed.
According to the Arrhenius model, the absolute temperature T
and the denaturation constant k are related according to the
empirical Arrhenius equation [123]
k~A|exp({Ea=RT) ð10Þ
where Ea is the activation energy of the denaturation reaction, A is
the pre-exponential factor (sometimes called the frequency factor)
which is assumed to be temperature-independent, and
R=8.3145 J/(K?mol)=1.987 cal/(K?mol) is the universal gas
constant.
Taking natural logarithms, equation (10) becomes:
1nk~1n(A){Ea=RT ð11Þ
For non-first-order kinetics, equation (11) can be modified as:
1nKapp~1n(A)z1n(C0
n{1){Ea=RT ð12Þ
When the natural logarithm of the denaturation rate constant
(or natural logarithm of the apparent rate constant) is plotted
against reciprocal temperature 1/T according to formulae (11)
and (12), an Arrhenius plot is obtained. For a single rate-limited
thermally activated process, an Arrhenius plot gives a straight line,
and the value of Ea can be obtained from the slope -Ea/R by
regression analysis.
According to the Bigelow model, by using D values, the Z value
[102,103], which is the temperature increase required for a 90%
decrease in D value, can be calculated by regression analysis from
the negative reciprocal slope of the line when the log10D values
versus temperature are plotted.
The inactivation temperature (Ti) can be defined as the
temperature when the half-life t1/2 of thermal denaturation is
equal to 10 minutes [80,82,126]. The value of Ti can be found by
regression analysis of the line when the log10(t1/2) values versus
temperature are plotted. This plot can be approximated as a
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log10(t1=2)~gTzf ð13Þ
and the value of Ti can be calculated as Ti=(12f)/g.
All fittings and linear regressions were carried out using the
Origin software package.
Supporting Information
Figure S1 Size of proteoliposomes. The non-extruded (A) and
extruded (B) CXCR4-proteoliposomes were analyzed by dynamic
light scattering (left) and by electron microscopy (right). The
dynamic light scattering analysis reveals the diameters of the
proteoliposomes in the non-extruded and extruded preparations;
the average diameter of the proteoliposomes in each population is
noted beneath the figures. The magnification of the electron
micrographs differ, as indicated by the scale bars.
Found at: doi:10.1371/journal.pone.0013249.s001 (1.52 MB TIF)
Figure S2 Protein composition of the proteoliposomes.
CXCR4-proteoliposomes (CXCR4-PL), CD4-proteoliposomes
(CD4-PL), or control proteoliposomes (PL) were lysed and
analyzed under nonreducing (2b-ME) or reducing (+b-ME)
conditions by SDS-PAGE. The gel was silver stained.
Found at: doi:10.1371/journal.pone.0013249.s002 (0.65 MB TIF)
Figure S3 Polyethylene glycol (PEG)-mediated fusion of cells
and proteoliposomes. The mean fluorescence intensity of 293T
cells mixed with rhodamine-labeled non-extruded or extruded
CXCR4-proteoliposomes is shown after treatment with PEG or,
as a control, in the absence of PEG.
Found at: doi:10.1371/journal.pone.0013249.s003 (0.15 MB TIF)
Figure S4 Association of CD4-proteoliposomes and CD4/
CXCR4-proteoliposomes with cells expressing HIV-1 envelope
glycoproteins. The median fluorescence intensity of 293T cells
expressing the HIV-1KB9 envelope glycoproteins (KB9) or
transfected with a plasmid containing the deleted DKS env gene
is shown, following incubation with D-PBS or rhodamine-labeled
CD4-proteoliposomes or rhodamine-labeled CD4/CXCR4-pro-
teoliposomes. The data shown represent the means and standard
deviations derived from triplicate experiments.
Found at: doi:10.1371/journal.pone.0013249.s004 (0.15 MB TIF)
Table S1 Inhibition of antibody binding to CD4/CXCR4-
proteoliposomes by ligands.
Found at: doi:10.1371/journal.pone.0013249.s005 (0.03 MB
DOC)
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